Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

NF2 (neurofibromatosis type 2)

Identity

Other namesSCH
HGNC NF2
Location 22q12.1-12.2
Local_order 22q12.1-12.2 junction, incidentally not far from EWS

DNA/RNA

Description exons 17 exons (1-15, 17 constitutive, 16 alternatively spliced); spans 120 kb; open reading frame: 1.8 kb
Transcription alternate splicing, in particular after exon 15

Protein

Description called merlin, schwannomin, or SCH; isoform 1 595 amino acids, isoform 2 590 amino acids (due to inclusion of exon 16 in transcript) ; 66 KDa; NH2 -- FERM domain -- large a helix domain -- COOH
Expression wide: in lung, kidney, ovary, breast, placenta, neuroblasts; high in fetal brain
Localisation membrane associated interacts with integral membrane proteins and actin-cytoskeleton
Function membrane-cytoskeleton anchor (as APC also appears to be); role in the development of extraembryonic structures before gastrulation; has characteristics of a tumour suppressor, as has been found in sporadic as well as neurofibromatosis type 2 induced schwannomas and meningiomas
Homology ezrin, radixin, moesin, members of the erythrocytes band 4.1 family, especially in the N-terminal FERM domain

Mutations

Germinal inborn condition of neurofibromatosis type 2 patients: protein truncations due to various frameshift deletions or insertions or nonsense mutations; splice-site or missense mutations are also found; phenotype-genotype correlations are observed (i.e. that severe phenotype are found in cases with protein truncations rather than those with amino acid substitution)
Somatic mutation and allele loss events in tumours in neurofibromatosis type 2 and in sporadic schwannomas and meningiomas are in accordance with the two-hit model for neoplasia, as is found in retinoblastoma

Implicated in

Entity neurofibromatosis type 2
Disease autosomal dominant tumor prone disease; neurofibromatosis type 2 (NF2: the same symbol is used for the disease neurofibromatosis type 2 and the gene) is an hamartoneoplastic syndrome
Prognosis hamartomas have a potential towards neoplasia; those, in NF2, are The tumors of NF2 are slow-growing benign schwannomas which do not progress to malignancy and meningiomas
  
Entity sporadic meningioma
  
Entity sporadic schwannoma
  
Entity other tumours: ependymoma; mesothelioma
  

External links

Nomenclature
HGNCNF2   7773
Entrez_GeneNF2  4771  neurofibromin 2 (merlin)
Cards
AtlasNF2117
GeneCardsNF2
EnsemblNF2 [Search_View]   ENSG00000186575 [Gene_View]
GenatlasNF2
GeneLynxNF2
eGenomeNF2
euGene4771
Genomic and cartography
GoldenPathNF2  -     chr22:28329545-28424589 +  22q12.2   [Description]    (hg18-Mar_2006)
EnsemblNF2 - 22q12.2 [CytoView]
NCBIMapview
OMIMDisease map [OMIM]
HomoloGeneNF2
Gene and transcription
GenbankAF113694 [ ENTREZ ]
GenbankAF122827 [ ENTREZ ]
GenbankAF122828 [ ENTREZ ]
GenbankAF123570 [ ENTREZ ]
GenbankAF369657 [ ENTREZ ]
RefSeqNM_000268 [ SRS ]    NM_000268 [ ENTREZ ]
RefSeqNM_016418 [ SRS ]    NM_016418 [ ENTREZ ]
RefSeqNM_181825 [ SRS ]    NM_181825 [ ENTREZ ]
RefSeqNM_181828 [ SRS ]    NM_181828 [ ENTREZ ]
RefSeqNM_181829 [ SRS ]    NM_181829 [ ENTREZ ]
RefSeqNM_181830 [ SRS ]    NM_181830 [ ENTREZ ]
RefSeqNM_181831 [ SRS ]    NM_181831 [ ENTREZ ]
RefSeqNM_181832 [ SRS ]    NM_181832 [ ENTREZ ]
RefSeqNM_181833 [ SRS ]    NM_181833 [ ENTREZ ]
RefSeqAC_000065 [ SRS ]    AC_000065 [ ENTREZ ]
RefSeqAC_000154 [ SRS ]    AC_000154 [ ENTREZ ]
RefSeqNC_000022 [ SRS ]    NC_000022 [ ENTREZ ]
RefSeqNT_011520 [ SRS ]    NT_011520 [ ENTREZ ]
RefSeqNW_001838745 [ SRS ]    NW_001838745 [ ENTREZ ]
RefSeqNW_927628 [ SRS ]    NW_927628 [ ENTREZ ]
AceViewNF2 AceView - NCBI
UnigeneHs.187898 [ SRS ]    Hs.187898 [ NCBI ]     HS187898 [ spliceNest ]
Fast-db3950 (alternative variants)
Protein : pattern, domain, 3D structure
SwissProtP35240 [ SRS]    P35240 [ EXPASY ]     P35240 [ INTERPRO ]     P35240 [ UNIPROT ]
PrositePS00660 FERM_1 [ SRS ]    PS00660 FERM_1 [ Expasy ]
PrositePS00661 FERM_2 [ SRS ]    PS00661 FERM_2 [ Expasy ]
PrositePS50057 FERM_3 [ SRS ]    PS50057 FERM_3 [ Expasy ]
InterproIPR000299 Band_4.1_N [ SRS ]    IPR000299 Band_4.1_N [ EBI ]
InterproIPR011174 ERM [ SRS ]    IPR011174 ERM [ EBI ]
InterproIPR011259 ERM_C [ SRS ]    IPR011259 ERM_C [ EBI ]
InterproIPR000798 Ez/rad/moesin [ SRS ]    IPR000798 Ez/rad/moesin [ EBI ]
InterproIPR014352 FERM/acyl-CoA_bd_prot_3-hlx [ SRS ]    IPR014352 FERM/acyl-CoA_bd_prot_3-hlx [ EBI ]
CluSTrP35240
PfamPF00373 Band_41 [ SRS ]    PF00373 Band_41 [ Sanger ]    pfam00373 [ NCBI-CDD ]
PfamPF00769 ERM [ SRS ]    PF00769 ERM [ Sanger ]    pfam00769 [ NCBI-CDD ]
SmartSM00295 B41 [EMBL]
BlocksP35240
PDB1H4R [ SRS ]    1H4R [ PdbSum ],   1H4R [ IMB ]   1H4R [ RSDB ]
HPRD06980
Protein Interaction databases
DIPP35240
IntActP35240
Polymorphism : SNP, mutations, diseases
OMIM101000;162091;607174;607379    [ map ]   
GENECLINICS101000;162091;607174;607379
SNPNF2 [dbSNP-NCBI]  
SNPNM_000268 [SNP-NCI]  
SNPNM_016418 [SNP-NCI]  
SNPNM_181825 [SNP-NCI]  
SNPNM_181828 [SNP-NCI]  
SNPNM_181829 [SNP-NCI]  
SNPNM_181830 [SNP-NCI]  
SNPNM_181831 [SNP-NCI]  
SNPNM_181832 [SNP-NCI]  
SNPNM_181833 [SNP-NCI]  
SNPNF2 [GeneSNPs - Utah]  NF2] [HGBASE - SRS]
HAPMAPNF2 [HAPMAP]  
COSMICNF2 [Somatic mutation (COSMIC-CGP-Sanger)]  
HGMDNF2
General knowledge
Family BrowserNF2 [UCSC Family Browser]
SOURCENM_000268
SOURCENM_016418
SOURCENM_181825
SOURCENM_181828
SOURCENM_181829
SOURCENM_181830
SOURCENM_181831
SOURCENM_181832
SOURCENM_181833
SMDHs.187898
SAGEHs.187898
GOnegative regulation of cell-matrix adhesion [Amigo]  negative regulation of cell-matrix adhesion
GOstructural molecule activity [Amigo]  structural molecule activity
GOnucleus [Amigo]  nucleus
GOnucleolus [Amigo]  nucleolus
GOcytoplasm [Amigo]  cytoplasm
GOearly endosome [Amigo]  early endosome
GOcytoskeleton [Amigo]  cytoskeleton
GOplasma membrane [Amigo]  plasma membrane
GOsensory perception of sound [Amigo]  sensory perception of sound
GOcytoskeletal protein binding [Amigo]  cytoskeletal protein binding
GOnegative regulation of DNA replication [Amigo]  negative regulation of DNA replication
GOnegative regulation of cell proliferation [Amigo]  negative regulation of cell proliferation
GOnegative regulation of cell proliferation [Amigo]  negative regulation of cell proliferation
GOSchwann cell proliferation [Amigo]  Schwann cell proliferation
GOextrinsic to membrane [Amigo]  extrinsic to membrane
GOnegative regulation of cell-cell adhesion [Amigo]  negative regulation of cell-cell adhesion
GOactin cytoskeleton organization and biogenesis [Amigo]  actin cytoskeleton organization and biogenesis
GOnegative regulation of cell migration [Amigo]  negative regulation of cell migration
GOnegative regulation of tyrosine phosphorylation of Stat3 protein [Amigo]  negative regulation of tyrosine phosphorylation of Stat3 protein
GOnegative regulation of tyrosine phosphorylation of Stat5 protein [Amigo]  negative regulation of tyrosine phosphorylation of Stat5 protein
GOcell projection [Amigo]  cell projection
GOnegative regulation of cell cycle [Amigo]  negative regulation of cell cycle
GOnegative regulation of JAK-STAT cascade [Amigo]  negative regulation of JAK-STAT cascade
GOperinuclear region of cytoplasm [Amigo]  perinuclear region of cytoplasm
GOpositive regulation of stress fiber formation [Amigo]  positive regulation of stress fiber formation
PubGeneNF2
TreeFamNF2
CTD4771 [Comparative ToxicoGenomics Database]
Other databases
Probes
ProbeNF2 Related clones (RZPD - Berlin)
PubMed
PubMed111 Pubmed reference(s) in Entrez

Bibliography

A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.
Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K
Cell. 1993 ; 72 (5) : 791-800.
PMID 8453669
 
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.
Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B
Nature. 1993 ; 363 (6429) : 515-521.
PMID 8379998
 
Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity.
Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N
American journal of medical genetics. 1994 ; 52 (4) : 450-461.
PMID 7747758
 
Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities.
Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M, Eldridge R, Gusella JF
American journal of human genetics. 1996 ; 59 (3) : 529-539.
PMID 8751853
 
Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease.
Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, Michels V, Riccardi VM, Weksberg R, Kitamura K, Bradburn JM, Hall BD, Propping P, Rouleau GA
American journal of human genetics. 1996 ; 59 (2) : 331-342.
PMID 8755919
 
The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation.
McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T
Genes & development. 1997 ; 11 (10) : 1253-1265.
PMID 9171370
 
Impaired interaction of naturally occurring mutant NF2 protein with actin-based cytoskeleton and membrane.
Deguen B, Mˆ©rel P, Goutebroze L, Giovannini M, Reggio H, Arpin M, Thomas G
Human molecular genetics. 1998 ; 7 (2) : 217-226.
PMID 9425229
 
Merlin: the neurofibromatosis 2 tumor suppressor.
Gusella JF, Ramesh V, MacCollin M, Jacoby LB
Biochimica et biophysica acta. 1999 ; 1423 (2) : M29-M36.
PMID 10214350
 
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.
Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff JM, Berns A, Thomas G
Genes & development. 2000 ; 14 (13) : 1617-1630.
PMID 10887156
 
The parental origin of new mutations in neurofibromatosis 2.
Kluwe L, Mautner V, Parry DM, Jacoby LB, Baser M, Gusella J, Davis K, Stavrou D, MacCollin M
Neurogenetics. 2000 ; 3 (1) : 17-24.
PMID 11085592
 
Advances in neurofibromatosis 2 (NF2): a workshop report.
Lim DJ, Rubenstein AE, Evans DG, Jacks T, Seizinger BG, Baser ME, Beebe D, Brackmann DE, Chiocca EA, Fehon RG, Giovannini M, Glazer R, Gusella JF, Gutmann DH, Korf B, Lieberman F, Martuza R, McClatchey AI, Parry DM, Pulst SM, Ramesh V, Ramsey WJ, Ratner N, Rutkowski JL, Ruttledge M, Weinstein DE
Journal of neurogenetics. 2000 ; 14 (2) : 63-106.
PMID 10992163
 
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

Contributor(s)

Written09-1997Jean-Loup Huret
Updated03-1998Jean-Loup Huret
Updated02-2001James F Gusella

Citation

This paper should be referenced as such :
Huret JL . NF2 (neurofibromatosis type 2). Atlas Genet Cytogenet Oncol Haematol. September 1997 .
URL : http://AtlasGeneticsOncology.org/Genes/NF2117.html
Huret JL . NF2 (neurofibromatosis type 2). Atlas Genet Cytogenet Oncol Haematol. March 1998 .
URL : http://AtlasGeneticsOncology.org/Genes/NF2117.html
Gusella JF . NF2 (neurofibromatosis type 2). Atlas Genet Cytogenet Oncol Haematol. February 2001 .
URL : http://AtlasGeneticsOncology.org/Genes/NF2117.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Sep 29 18:43:06 2008


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

j.l.huret@chu-poitiers.fr.